TG Therapeutics (TGTX) Jefferies Global Healthcare Conference 2026 summary

Company overview and commercial progress

• BRIUMVI has been on the market for 3.5 years, with projected 2026 U.S. sales of $885M–$900M.

• Achieved number one dynamic market share in the private practice infusion center sector for CD20 therapies.

• Ongoing strategy is to expand market share in both IV and, soon, SUB-Q segments.

• Active share buyback program reflects management's view of undervaluation.

SUB-Q BRIUMVI development and data insights

• Announced positive phase I SUB-Q BRIUMVI data, showing 60% bioavailability and strong safety profile.

• Phase III SUB-Q trial is fully enrolled; data expected by year-end 2026, with launch targeted for 2028.

• Modeling predicts a 1.2 exposure ratio, well above the 0.8 non-inferiority threshold, indicating high likelihood of phase III success.

• SUB-Q formulation enables entry into the 35–40% of the market preferring self-injection, potentially doubling addressable market.

• Plan to launch with an auto-injector device for at-home use.

Market dynamics and competitive positioning

• CD20 market is split between HCP-administered IV (60–65%) and SUB-Q (35–40%) self-injection.

• SUB-Q BRIUMVI could expand the overall CD20 market, especially among community neurologists without infusion capabilities.

• Every three-month SUB-Q dosing is seen as a potential game changer for patient convenience and market uptake.

• Having both IV and SUB-Q options positions the company uniquely among CD20 MS competitors.